Thomas Kelly Jr
Concepts (369)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Serine Endopeptidases | 11 | 2016 | 51 | 1.950 |
Why?
| Gelatinases | 11 | 2016 | 32 | 1.930 |
Why?
| Membrane Proteins | 16 | 2023 | 332 | 1.790 |
Why?
| Schizosaccharomyces | 6 | 2016 | 60 | 1.720 |
Why?
| Breast Neoplasms | 14 | 2024 | 1200 | 1.430 |
Why?
| DNA Replication | 5 | 2016 | 156 | 1.040 |
Why?
| Neoplasm Invasiveness | 9 | 2016 | 269 | 0.890 |
Why?
| Glucuronidase | 5 | 2010 | 48 | 0.840 |
Why?
| Cocaine | 4 | 2024 | 182 | 0.760 |
Why?
| Students, Medical | 1 | 2023 | 162 | 0.740 |
Why?
| DNA, Fungal | 3 | 2016 | 46 | 0.650 |
Why?
| Ultraviolet Rays | 2 | 2010 | 49 | 0.610 |
Why?
| Neoplasms | 4 | 2023 | 1255 | 0.590 |
Why?
| Neoplasm Metastasis | 8 | 2011 | 232 | 0.570 |
Why?
| Endopeptidases | 13 | 2016 | 65 | 0.570 |
Why?
| Cell Cycle | 2 | 2010 | 226 | 0.560 |
Why?
| Adenocarcinoma | 3 | 2005 | 396 | 0.540 |
Why?
| Animals | 33 | 2024 | 13124 | 0.530 |
Why?
| G2 Phase Cell Cycle Checkpoints | 1 | 2016 | 9 | 0.510 |
Why?
| Gene Expression Regulation, Fungal | 1 | 2016 | 52 | 0.500 |
Why?
| DNA Repair | 1 | 2016 | 188 | 0.460 |
Why?
| Proteoglycans | 5 | 2023 | 83 | 0.460 |
Why?
| Extracellular Matrix | 6 | 2005 | 109 | 0.450 |
Why?
| Syndecan-1 | 4 | 2010 | 75 | 0.450 |
Why?
| Medical Oncology | 2 | 2023 | 99 | 0.440 |
Why?
| Cell Movement | 4 | 2019 | 247 | 0.430 |
Why?
| Cell Line, Tumor | 10 | 2020 | 1398 | 0.420 |
Why?
| DNA Damage | 3 | 2016 | 301 | 0.420 |
Why?
| Disease | 1 | 2012 | 25 | 0.380 |
Why?
| Mice | 12 | 2023 | 5687 | 0.380 |
Why?
| Cellular Microenvironment | 1 | 2012 | 27 | 0.380 |
Why?
| Cell Membrane | 9 | 2005 | 246 | 0.370 |
Why?
| Dopaminergic Neurons | 4 | 2023 | 18 | 0.370 |
Why?
| Cell Cycle Proteins | 3 | 2020 | 161 | 0.360 |
Why?
| Cocaine-Related Disorders | 2 | 2024 | 209 | 0.360 |
Why?
| Humans | 44 | 2024 | 50516 | 0.360 |
Why?
| Vulvar Neoplasms | 3 | 2016 | 58 | 0.360 |
Why?
| Fructose | 1 | 2010 | 22 | 0.350 |
Why?
| Antigens, Neoplasm | 2 | 2011 | 148 | 0.350 |
Why?
| Dipeptidyl Peptidase 4 | 3 | 2011 | 10 | 0.350 |
Why?
| Carbon | 1 | 2010 | 55 | 0.340 |
Why?
| Stromal Cells | 3 | 2016 | 75 | 0.340 |
Why?
| Schizosaccharomyces pombe Proteins | 4 | 2016 | 42 | 0.330 |
Why?
| Cytoskeletal Proteins | 3 | 2020 | 47 | 0.330 |
Why?
| Neovascularization, Pathologic | 3 | 2005 | 155 | 0.320 |
Why?
| Membrane Glycoproteins | 6 | 2005 | 245 | 0.320 |
Why?
| Multiple Myeloma | 6 | 2004 | 2998 | 0.310 |
Why?
| Origin Recognition Complex | 1 | 2008 | 2 | 0.310 |
Why?
| Bone and Bones | 2 | 2010 | 478 | 0.310 |
Why?
| Carcinoma, Squamous Cell | 3 | 2016 | 326 | 0.300 |
Why?
| Heparan Sulfate Proteoglycans | 2 | 2005 | 11 | 0.300 |
Why?
| Mammary Neoplasms, Experimental | 2 | 2005 | 121 | 0.290 |
Why?
| Female | 22 | 2024 | 27086 | 0.280 |
Why?
| Osteogenesis | 1 | 2010 | 356 | 0.280 |
Why?
| Tumor Cells, Cultured | 7 | 2010 | 457 | 0.280 |
Why?
| RNA, Messenger | 4 | 2023 | 1089 | 0.280 |
Why?
| Cell Adhesion | 7 | 2020 | 157 | 0.280 |
Why?
| Bone Resorption | 2 | 2010 | 302 | 0.280 |
Why?
| Osteoclasts | 1 | 2010 | 427 | 0.280 |
Why?
| Bone Neoplasms | 2 | 2005 | 179 | 0.250 |
Why?
| Mice, SCID | 4 | 2010 | 178 | 0.250 |
Why?
| Pyrimidines | 2 | 2021 | 191 | 0.250 |
Why?
| Oligosaccharides | 1 | 2005 | 34 | 0.250 |
Why?
| Antibodies, Neoplasm | 1 | 2005 | 28 | 0.250 |
Why?
| Peripheral Nerves | 2 | 2015 | 48 | 0.240 |
Why?
| DNA | 1 | 2008 | 535 | 0.240 |
Why?
| Guanine Nucleotide Exchange Factors | 1 | 2024 | 18 | 0.240 |
Why?
| Nanostructures | 1 | 2005 | 45 | 0.240 |
Why?
| Receptors, AMPA | 1 | 2024 | 18 | 0.240 |
Why?
| Education, Medical, Undergraduate | 1 | 2006 | 86 | 0.240 |
Why?
| Nucleus Accumbens | 1 | 2024 | 26 | 0.240 |
Why?
| Pseudohypoaldosteronism | 1 | 2024 | 5 | 0.230 |
Why?
| Receptors, Mineralocorticoid | 1 | 2024 | 9 | 0.230 |
Why?
| Synapses | 1 | 2024 | 85 | 0.230 |
Why?
| Gene Expression Regulation, Neoplastic | 3 | 2019 | 833 | 0.230 |
Why?
| Extinction, Psychological | 1 | 2023 | 34 | 0.220 |
Why?
| Metalloendopeptidases | 3 | 1998 | 69 | 0.210 |
Why?
| gamma-Aminobutyric Acid | 1 | 2023 | 65 | 0.210 |
Why?
| Research | 1 | 2023 | 106 | 0.210 |
Why?
| Actins | 5 | 2020 | 114 | 0.210 |
Why?
| Fear | 1 | 2023 | 84 | 0.200 |
Why?
| Phosphorylation | 4 | 2020 | 525 | 0.200 |
Why?
| Biomedical Research | 1 | 2006 | 244 | 0.200 |
Why?
| Serotonin | 1 | 2023 | 151 | 0.200 |
Why?
| Cell Proliferation | 5 | 2019 | 985 | 0.200 |
Why?
| DNA-Directed DNA Polymerase | 2 | 2016 | 90 | 0.200 |
Why?
| Parkinson Disease, Secondary | 1 | 2021 | 7 | 0.190 |
Why?
| Program Evaluation | 1 | 2023 | 349 | 0.190 |
Why?
| Pyrans | 1 | 2021 | 16 | 0.190 |
Why?
| Drug-Seeking Behavior | 1 | 2021 | 5 | 0.190 |
Why?
| Phosphodiesterase Inhibitors | 1 | 2021 | 25 | 0.190 |
Why?
| Reinforcement Schedule | 1 | 2021 | 76 | 0.190 |
Why?
| Cues | 1 | 2021 | 51 | 0.190 |
Why?
| Collagenases | 2 | 1999 | 24 | 0.180 |
Why?
| Receptor, Cannabinoid, CB2 | 1 | 2021 | 57 | 0.180 |
Why?
| Neoplasm Proteins | 4 | 1998 | 320 | 0.180 |
Why?
| Internal Mammary-Coronary Artery Anastomosis | 1 | 2020 | 5 | 0.180 |
Why?
| Curriculum | 1 | 2023 | 400 | 0.180 |
Why?
| Radial Artery | 1 | 2020 | 31 | 0.170 |
Why?
| Pyridines | 1 | 2021 | 131 | 0.170 |
Why?
| Behavior, Animal | 1 | 2021 | 178 | 0.170 |
Why?
| Collagen Type I | 2 | 2016 | 81 | 0.170 |
Why?
| Cyclin-Dependent Kinase 5 | 1 | 2020 | 1 | 0.170 |
Why?
| Neurons | 1 | 2023 | 452 | 0.170 |
Why?
| Matrix Metalloproteinases | 1 | 2000 | 46 | 0.170 |
Why?
| Actin Cytoskeleton | 1 | 2020 | 21 | 0.170 |
Why?
| Signal Transduction | 7 | 2020 | 1624 | 0.170 |
Why?
| Immunohistochemistry | 5 | 2016 | 957 | 0.170 |
Why?
| Cyclic AMP | 1 | 2020 | 90 | 0.170 |
Why?
| Lung Neoplasms | 1 | 2005 | 600 | 0.170 |
Why?
| Parkinson Disease | 1 | 2021 | 160 | 0.160 |
Why?
| Cell Division | 3 | 2004 | 291 | 0.160 |
Why?
| Pancreas | 1 | 2019 | 71 | 0.160 |
Why?
| Ventral Tegmental Area | 3 | 2023 | 8 | 0.150 |
Why?
| Mice, Inbred BALB C | 2 | 2011 | 296 | 0.150 |
Why?
| Cell Transformation, Neoplastic | 1 | 2019 | 181 | 0.150 |
Why?
| Protein Processing, Post-Translational | 1 | 2019 | 156 | 0.150 |
Why?
| Phenotype | 3 | 2010 | 739 | 0.150 |
Why?
| Carcinoma, Ductal, Breast | 1 | 1998 | 91 | 0.140 |
Why?
| Catalytic Domain | 2 | 2009 | 58 | 0.140 |
Why?
| Coronary Artery Disease | 1 | 2020 | 278 | 0.130 |
Why?
| Time-Lapse Imaging | 1 | 2016 | 3 | 0.130 |
Why?
| Epithelial-Mesenchymal Transition | 1 | 2016 | 51 | 0.130 |
Why?
| Rad51 Recombinase | 1 | 2016 | 23 | 0.130 |
Why?
| Rats | 4 | 2024 | 3292 | 0.130 |
Why?
| Nucleotidyltransferases | 1 | 2016 | 14 | 0.130 |
Why?
| Protein Kinases | 2 | 2006 | 71 | 0.130 |
Why?
| Scavenger Receptors, Class A | 1 | 2016 | 39 | 0.130 |
Why?
| Mitosis | 1 | 2016 | 88 | 0.120 |
Why?
| Cell Transformation, Viral | 3 | 1994 | 25 | 0.120 |
Why?
| Fibroma | 1 | 2015 | 37 | 0.120 |
Why?
| Syndecans | 4 | 2005 | 37 | 0.120 |
Why?
| Avian Sarcoma Viruses | 2 | 1994 | 5 | 0.120 |
Why?
| Models, Biological | 3 | 2008 | 716 | 0.120 |
Why?
| Enzyme Activation | 3 | 2006 | 268 | 0.120 |
Why?
| Neoplasm Transplantation | 2 | 2005 | 86 | 0.120 |
Why?
| Fibroblasts | 3 | 1994 | 336 | 0.120 |
Why?
| Transplantation, Heterologous | 2 | 2005 | 75 | 0.120 |
Why?
| Transfection | 3 | 2004 | 356 | 0.120 |
Why?
| Extracellular Matrix Proteins | 2 | 1994 | 68 | 0.120 |
Why?
| Neoplasm Recurrence, Local | 2 | 2015 | 629 | 0.110 |
Why?
| Recombinant Proteins | 3 | 2016 | 476 | 0.110 |
Why?
| Peptide Hydrolases | 2 | 1994 | 61 | 0.110 |
Why?
| Male | 8 | 2024 | 25913 | 0.110 |
Why?
| Cytoskeleton | 3 | 1989 | 39 | 0.110 |
Why?
| Self Administration | 2 | 2024 | 97 | 0.100 |
Why?
| Aged, 80 and over | 5 | 2020 | 3227 | 0.100 |
Why?
| Macrophages | 1 | 2016 | 364 | 0.100 |
Why?
| Wnt1 Protein | 1 | 2012 | 10 | 0.100 |
Why?
| Mammary Neoplasms, Animal | 1 | 2012 | 35 | 0.100 |
Why?
| Phytotherapy | 1 | 2012 | 45 | 0.100 |
Why?
| Cadherins | 3 | 2016 | 63 | 0.100 |
Why?
| Interleukin-8 | 2 | 2010 | 85 | 0.100 |
Why?
| Chick Embryo | 5 | 1999 | 83 | 0.100 |
Why?
| Serine Proteinase Inhibitors | 1 | 2012 | 10 | 0.100 |
Why?
| Organ Specificity | 1 | 2012 | 109 | 0.100 |
Why?
| Microscopy, Phase-Contrast | 1 | 2010 | 12 | 0.090 |
Why?
| Plant Lectins | 1 | 2010 | 8 | 0.090 |
Why?
| PAX2 Transcription Factor | 1 | 2010 | 22 | 0.090 |
Why?
| Prenatal Exposure Delayed Effects | 1 | 2012 | 182 | 0.090 |
Why?
| Culture Media, Conditioned | 1 | 2010 | 47 | 0.090 |
Why?
| Carcinoma, Papillary | 1 | 2010 | 47 | 0.090 |
Why?
| Glycosylation | 1 | 2010 | 102 | 0.090 |
Why?
| Insulin | 1 | 2012 | 467 | 0.090 |
Why?
| Substrate Specificity | 1 | 2010 | 192 | 0.090 |
Why?
| Carcinoma, Renal Cell | 1 | 2010 | 101 | 0.080 |
Why?
| Magnetics | 1 | 2009 | 35 | 0.080 |
Why?
| Acoustics | 1 | 2009 | 33 | 0.080 |
Why?
| Light | 1 | 2009 | 69 | 0.080 |
Why?
| Phosphopeptides | 1 | 2009 | 6 | 0.080 |
Why?
| Kidney Neoplasms | 1 | 2010 | 174 | 0.080 |
Why?
| Culture Media | 1 | 2009 | 93 | 0.080 |
Why?
| Sequence Deletion | 1 | 2009 | 67 | 0.080 |
Why?
| Neoplastic Cells, Circulating | 1 | 2009 | 74 | 0.080 |
Why?
| Neoplasm Staging | 3 | 2016 | 746 | 0.080 |
Why?
| DNA Topoisomerases, Type I | 1 | 2008 | 3 | 0.080 |
Why?
| DNA, Superhelical | 1 | 2008 | 4 | 0.080 |
Why?
| Salts | 1 | 2008 | 9 | 0.080 |
Why?
| Plasmids | 1 | 2009 | 164 | 0.080 |
Why?
| Protein Structure, Tertiary | 3 | 2005 | 245 | 0.080 |
Why?
| Antibodies | 1 | 2009 | 153 | 0.080 |
Why?
| Replication Origin | 1 | 2008 | 10 | 0.080 |
Why?
| Diet | 1 | 2012 | 568 | 0.080 |
Why?
| Amino Acid Motifs | 1 | 2008 | 55 | 0.080 |
Why?
| Aged | 7 | 2020 | 9743 | 0.080 |
Why?
| Mesoderm | 1 | 2008 | 26 | 0.070 |
Why?
| Early Detection of Cancer | 1 | 2009 | 163 | 0.070 |
Why?
| Escherichia coli | 1 | 2009 | 190 | 0.070 |
Why?
| Polymerase Chain Reaction | 1 | 2009 | 449 | 0.070 |
Why?
| Muscle, Smooth | 1 | 1987 | 61 | 0.070 |
Why?
| Disease Models, Animal | 2 | 2021 | 1436 | 0.070 |
Why?
| Integrins | 3 | 2016 | 30 | 0.070 |
Why?
| Protein Binding | 2 | 2008 | 654 | 0.070 |
Why?
| Mutation | 2 | 2019 | 1281 | 0.070 |
Why?
| DNA, Mitochondrial | 1 | 2008 | 111 | 0.070 |
Why?
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2012 | 572 | 0.070 |
Why?
| Glycoproteins | 1 | 1987 | 116 | 0.070 |
Why?
| Middle Aged | 7 | 2020 | 12613 | 0.070 |
Why?
| Epithelial Cells | 1 | 2008 | 207 | 0.070 |
Why?
| Breast | 2 | 2016 | 85 | 0.070 |
Why?
| Blotting, Western | 3 | 2012 | 578 | 0.070 |
Why?
| DNA, Complementary | 2 | 2004 | 133 | 0.070 |
Why?
| Dimerization | 1 | 2006 | 51 | 0.070 |
Why?
| Lymphatic Metastasis | 2 | 2015 | 222 | 0.060 |
Why?
| E-Selectin | 1 | 2005 | 14 | 0.060 |
Why?
| Pancreatic Neoplasms | 1 | 2008 | 206 | 0.060 |
Why?
| Cell Line | 1 | 2008 | 988 | 0.060 |
Why?
| Metals | 1 | 2005 | 35 | 0.060 |
Why?
| Phototherapy | 1 | 2005 | 42 | 0.060 |
Why?
| Chi-Square Distribution | 2 | 2016 | 277 | 0.060 |
Why?
| Ligands | 1 | 2005 | 203 | 0.060 |
Why?
| Time Factors | 3 | 2015 | 2935 | 0.060 |
Why?
| Immunoblotting | 2 | 2003 | 115 | 0.060 |
Why?
| Fungal Proteins | 1 | 2006 | 123 | 0.060 |
Why?
| Carcinogens | 2 | 2005 | 196 | 0.060 |
Why?
| Heparitin Sulfate | 1 | 2004 | 9 | 0.060 |
Why?
| Fibronectins | 2 | 1998 | 38 | 0.060 |
Why?
| Career Choice | 1 | 2006 | 112 | 0.060 |
Why?
| Hyperthermia, Induced | 1 | 2005 | 115 | 0.060 |
Why?
| Matrix Metalloproteinase 9 | 3 | 2002 | 88 | 0.060 |
Why?
| Gold | 1 | 2005 | 128 | 0.060 |
Why?
| Growth Substances | 2 | 2003 | 21 | 0.060 |
Why?
| Antibodies, Monoclonal | 3 | 2023 | 462 | 0.060 |
Why?
| Osteolysis | 1 | 2004 | 74 | 0.060 |
Why?
| Microscopy, Fluorescence | 2 | 2003 | 158 | 0.060 |
Why?
| Microfilament Proteins | 2 | 2020 | 42 | 0.050 |
Why?
| Odds Ratio | 2 | 2015 | 551 | 0.050 |
Why?
| Cells, Cultured | 4 | 2016 | 1571 | 0.050 |
Why?
| Receptors, Lipoprotein | 1 | 2003 | 7 | 0.050 |
Why?
| Gene Deletion | 1 | 2024 | 261 | 0.050 |
Why?
| Lipoproteins, HDL | 1 | 2003 | 18 | 0.050 |
Why?
| Receptors, Immunologic | 1 | 2003 | 35 | 0.050 |
Why?
| Vimentin | 2 | 2016 | 32 | 0.050 |
Why?
| Nitric Oxide Synthase | 1 | 2003 | 74 | 0.050 |
Why?
| Chondroitin Sulfate Proteoglycans | 1 | 2023 | 18 | 0.050 |
Why?
| Eukaryotic Cells | 1 | 2003 | 15 | 0.050 |
Why?
| Oligonucleotides, Antisense | 1 | 2003 | 27 | 0.050 |
Why?
| Blotting, Northern | 1 | 2003 | 110 | 0.050 |
Why?
| Antigens, Tumor-Associated, Carbohydrate | 1 | 2023 | 24 | 0.050 |
Why?
| Calcium | 1 | 2024 | 398 | 0.050 |
Why?
| Logistic Models | 2 | 2015 | 899 | 0.050 |
Why?
| Cloning, Molecular | 1 | 2003 | 190 | 0.050 |
Why?
| Cell Separation | 1 | 2003 | 92 | 0.050 |
Why?
| Treatment Outcome | 3 | 2020 | 5285 | 0.050 |
Why?
| Mesencephalon | 1 | 2022 | 36 | 0.050 |
Why?
| Mucous Membrane | 1 | 2002 | 28 | 0.050 |
Why?
| Models, Genetic | 1 | 2003 | 172 | 0.050 |
Why?
| Molecular Weight | 3 | 1994 | 82 | 0.050 |
Why?
| Rectum | 1 | 2002 | 52 | 0.050 |
Why?
| Oxidopamine | 1 | 2021 | 4 | 0.050 |
Why?
| Tumor Microenvironment | 1 | 2024 | 222 | 0.050 |
Why?
| Up-Regulation | 1 | 2023 | 446 | 0.050 |
Why?
| Rats, Long-Evans | 1 | 2021 | 26 | 0.050 |
Why?
| Bone Marrow | 1 | 2003 | 363 | 0.050 |
Why?
| Estradiol | 1 | 2003 | 221 | 0.050 |
Why?
| Dopamine | 1 | 2022 | 175 | 0.050 |
Why?
| Carcinoma | 1 | 2003 | 137 | 0.050 |
Why?
| Endothelium, Vascular | 1 | 2003 | 251 | 0.050 |
Why?
| Adult | 5 | 2016 | 13584 | 0.050 |
Why?
| Neuronal Plasticity | 1 | 2021 | 58 | 0.050 |
Why?
| Biopsy | 2 | 2015 | 588 | 0.050 |
Why?
| Retrospective Studies | 3 | 2020 | 6264 | 0.050 |
Why?
| Gene Expression Regulation | 1 | 2005 | 955 | 0.050 |
Why?
| Rats, Sprague-Dawley | 1 | 2024 | 1585 | 0.050 |
Why?
| Neuroprotective Agents | 1 | 2021 | 99 | 0.040 |
Why?
| Australia | 1 | 2020 | 86 | 0.040 |
Why?
| Actin Depolymerizing Factors | 1 | 2020 | 5 | 0.040 |
Why?
| Thiazolidines | 1 | 2020 | 5 | 0.040 |
Why?
| Flow Cytometry | 1 | 2003 | 474 | 0.040 |
Why?
| Focal Adhesion Protein-Tyrosine Kinases | 1 | 2020 | 20 | 0.040 |
Why?
| Propensity Score | 1 | 2020 | 136 | 0.040 |
Why?
| Collagen | 2 | 1998 | 204 | 0.040 |
Why?
| Stress Fibers | 1 | 2019 | 5 | 0.040 |
Why?
| HEK293 Cells | 1 | 2020 | 213 | 0.040 |
Why?
| Focal Adhesion Kinase 1 | 1 | 2019 | 15 | 0.040 |
Why?
| HeLa Cells | 1 | 2020 | 247 | 0.040 |
Why?
| Platelet-Derived Growth Factor | 1 | 2019 | 22 | 0.040 |
Why?
| Mitogen-Activated Protein Kinase 3 | 1 | 2019 | 49 | 0.040 |
Why?
| Mitogen-Activated Protein Kinase 1 | 1 | 2019 | 50 | 0.040 |
Why?
| Evaluation Studies as Topic | 1 | 1999 | 107 | 0.040 |
Why?
| Gene Expression Profiling | 1 | 2003 | 1025 | 0.040 |
Why?
| Bone Remodeling | 1 | 2000 | 149 | 0.040 |
Why?
| Pseudopodia | 1 | 1998 | 3 | 0.040 |
Why?
| Prostatic Neoplasms | 1 | 2002 | 384 | 0.040 |
Why?
| RNA, Small Interfering | 1 | 2019 | 208 | 0.040 |
Why?
| Thiophenes | 1 | 1998 | 36 | 0.040 |
Why?
| Linear Models | 1 | 1999 | 279 | 0.040 |
Why?
| Dose-Response Relationship, Drug | 1 | 2021 | 1372 | 0.040 |
Why?
| Survival Rate | 1 | 2020 | 909 | 0.040 |
Why?
| Phenylalanine | 1 | 1998 | 134 | 0.040 |
Why?
| Antineoplastic Agents | 1 | 2005 | 1172 | 0.040 |
Why?
| Databases, Factual | 1 | 2020 | 674 | 0.040 |
Why?
| Infant, Newborn | 1 | 2024 | 2749 | 0.030 |
Why?
| Risk Factors | 2 | 2015 | 3723 | 0.030 |
Why?
| Lymph Nodes | 1 | 1998 | 257 | 0.030 |
Why?
| Enzyme Inhibitors | 1 | 1998 | 377 | 0.030 |
Why?
| Anion Exchange Protein 1, Erythrocyte | 1 | 2015 | 8 | 0.030 |
Why?
| Young Adult | 2 | 2015 | 4107 | 0.030 |
Why?
| beta Catenin | 1 | 2016 | 97 | 0.030 |
Why?
| Antiporters | 1 | 2015 | 19 | 0.030 |
Why?
| Mice, Inbred C57BL | 2 | 2016 | 1808 | 0.030 |
Why?
| S100 Proteins | 1 | 2015 | 33 | 0.030 |
Why?
| Antigens, CD | 1 | 2016 | 222 | 0.030 |
Why?
| Neoplasm, Residual | 1 | 2015 | 160 | 0.030 |
Why?
| Multivariate Analysis | 1 | 2015 | 583 | 0.030 |
Why?
| Protease Inhibitors | 1 | 1994 | 58 | 0.030 |
Why?
| Immunoenzyme Techniques | 1 | 2012 | 137 | 0.030 |
Why?
| Disease Progression | 1 | 2015 | 829 | 0.030 |
Why?
| Lactation | 1 | 2012 | 58 | 0.030 |
Why?
| Real-Time Polymerase Chain Reaction | 1 | 2012 | 181 | 0.020 |
Why?
| Cell Nucleus | 2 | 2010 | 182 | 0.020 |
Why?
| Melanoma | 1 | 1994 | 280 | 0.020 |
Why?
| Mice, Transgenic | 1 | 2012 | 540 | 0.020 |
Why?
| Cross Reactions | 2 | 1987 | 39 | 0.020 |
Why?
| Rheology | 1 | 2009 | 7 | 0.020 |
Why?
| Molecular Mimicry | 1 | 2009 | 38 | 0.020 |
Why?
| Matrix Metalloproteinase 2 | 2 | 2002 | 59 | 0.020 |
Why?
| Receptors, Transforming Growth Factor beta | 1 | 2008 | 25 | 0.020 |
Why?
| Sensitivity and Specificity | 1 | 2010 | 861 | 0.020 |
Why?
| Nanoparticles | 1 | 2009 | 152 | 0.020 |
Why?
| Predictive Value of Tests | 1 | 2010 | 930 | 0.020 |
Why?
| Microscopy, Electron | 1 | 1987 | 77 | 0.020 |
Why?
| Transforming Growth Factor beta | 1 | 2008 | 136 | 0.020 |
Why?
| Chickens | 1 | 1987 | 111 | 0.020 |
Why?
| Diagnosis, Differential | 1 | 2010 | 1033 | 0.020 |
Why?
| Kidney | 1 | 2010 | 696 | 0.020 |
Why?
| Fibroblast Growth Factor 2 | 1 | 2005 | 34 | 0.020 |
Why?
| Pregnancy | 1 | 2012 | 2451 | 0.020 |
Why?
| Vascular Endothelial Growth Factor A | 1 | 2005 | 182 | 0.010 |
Why?
| Scavenger Receptors, Class B | 1 | 2003 | 10 | 0.010 |
Why?
| Nitric Oxide Synthase Type II | 1 | 2003 | 65 | 0.010 |
Why?
| Receptors, Scavenger | 1 | 2003 | 29 | 0.010 |
Why?
| Hormone Replacement Therapy | 1 | 2003 | 33 | 0.010 |
Why?
| Spectrin | 1 | 1982 | 3 | 0.010 |
Why?
| Ovariectomy | 1 | 2003 | 115 | 0.010 |
Why?
| Nitric Oxide Synthase Type III | 1 | 2003 | 78 | 0.010 |
Why?
| Brain Chemistry | 1 | 1982 | 69 | 0.010 |
Why?
| Vasodilation | 1 | 2003 | 98 | 0.010 |
Why?
| Femoral Artery | 1 | 2003 | 106 | 0.010 |
Why?
| Protein Transport | 1 | 2003 | 181 | 0.010 |
Why?
| Endoscopy | 1 | 2002 | 119 | 0.010 |
Why?
| Neutrophils | 1 | 2002 | 145 | 0.010 |
Why?
| Sex Factors | 1 | 2003 | 711 | 0.010 |
Why?
| Mice, Knockout | 1 | 2003 | 844 | 0.010 |
Why?
| beta 2-Microglobulin | 1 | 1997 | 39 | 0.010 |
Why?
| Rhodamines | 1 | 1993 | 5 | 0.010 |
Why?
| Cell Adhesion Molecules | 1 | 1994 | 86 | 0.010 |
Why?
| Tissue Inhibitor of Metalloproteinase-2 | 1 | 1993 | 12 | 0.010 |
Why?
| Gelatin | 1 | 1993 | 23 | 0.010 |
Why?
| Biotin | 1 | 1993 | 46 | 0.010 |
Why?
| Binding Sites | 1 | 1993 | 362 | 0.010 |
Why?
| Amino Acid Sequence | 1 | 1993 | 574 | 0.010 |
Why?
| Molecular Sequence Data | 1 | 1993 | 778 | 0.010 |
Why?
| Talin | 1 | 1989 | 3 | 0.010 |
Why?
| Concanavalin A | 1 | 1989 | 11 | 0.010 |
Why?
| Microspheres | 1 | 1989 | 27 | 0.010 |
Why?
| Cell Line, Transformed | 1 | 1989 | 73 | 0.010 |
Why?
| Vinculin | 1 | 1982 | 3 | 0.000 |
Why?
| Actinin | 1 | 1982 | 2 | 0.000 |
Why?
| Immune Sera | 1 | 1982 | 15 | 0.000 |
Why?
| Erythrocyte Membrane | 1 | 1982 | 14 | 0.000 |
Why?
| Ankyrins | 1 | 1982 | 9 | 0.000 |
Why?
| Electrophoresis, Polyacrylamide Gel | 1 | 1982 | 98 | 0.000 |
Why?
| Fluorescent Antibody Technique | 1 | 1982 | 104 | 0.000 |
Why?
| Epitopes | 1 | 1982 | 59 | 0.000 |
Why?
| Cattle | 1 | 1982 | 205 | 0.000 |
Why?
| Terminology as Topic | 1 | 1982 | 67 | 0.000 |
Why?
| Swine | 1 | 1982 | 408 | 0.000 |
Why?
| Muscle Proteins | 1 | 1982 | 320 | 0.000 |
Why?
|
|
Kelly Jr's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|